We advocate for compounding pharmacies and facilities on a range of state and federal issues affecting patient access to compounded medications. We represent pharmacists and technicians in both traditional 503A compounding pharmacies and 503B outsourcing facilities, as well as prescribers, patients, educators, and suppliers. We’re 5,000 members strong and growing.
APC sent members of FDA’s Pharmacy Compounding Advisory Committee a briefing memo on how and why traditional 503A pharmacy compounding works.
This month, NABP published the updated model, and a lot of APC's fingerprints are on it.
Sarah Derr, PharmD, MPS, joined the APC staff this week. She is former Minnesota Pharmacists Association executive director and CEO.
FDA issued a safety communication following adverse events associated with compounded IV glutathione made with dietary supplement-grade glutathione.
FDA has named Clint Narver as the permanent director of the Office of Compounding Quality and Compliance. Edisa Gozun, PharmD, will serve as deputy ...
.png?width=410&height=320&name=image-container%20(1).png)
.png?width=410&height=320&name=image-container%20(2).png)
.png?width=411&height=320&name=image-container%20(3).png)
.png?width=410&height=320&name=image-container%20(4).png)
.png)
.png?width=17&height=16&name=folder%20(1).png){kind=small}
%20Pharma-GS.png)
